Farhad Shahram

Farhad Shahram

Auto-generated profile, based on publicly available information

Farhad Shahram

Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 3439123900, Iran

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
I(International Team for the Revision of the International Criteria for Behçet's Disease (ITR‐ICBD)
International Team for the Revision of the International Criteria for Behçet's Disease (ITR‐ICBD)
FDF. Davatchi
F. Davatchi
SAS. Assaad‐Khalil
S. Assaad‐Khalil
KCK.T. Calamia
K.T. Calamia
JCJ.E. Crook
J.E. Crook
NZN. Ziaei
N. Ziaei

11 July 2016 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
FDFereydoun Davatchi
Fereydoun Davatchi
CCCheyda Chams-Davatchi
Cheyda Chams-Davatchi
HSHormoz Shams
Hormoz Shams
FSFarhad Shahram
Farhad Shahram
ANAbdolhadi Nadji
Abdolhadi Nadji
MMMariam Masoumi
Mariam Masoumi
Introduction: Behcet’s Disease (BD) is classified among vasculitides. The aim of this review was to put together different known reports in order to help the reader to better understand the disease, to avoid the frequent misdiagnosis, and to decide the best treatment. Areas covered: a) Epidemiology: BD is rare, and is seen along the Silk Road, from 20 to 420/100,000 in Turkey and 80/100,000 in Iran, to 0.64/100,000 in the UK. b) Clinical manifestations: oral aphthosis is seen in more than 95% of patients, genital aphthosis (60–90%), skin (pseudofolliculitis/erythema nodosum, 40–90%), eyes (uveitis/retinal vasculitis, 45–90%), gastrointestinal (diarrhea/hemorrhage/perforation/pain, 4–38%), vascular (venous/arterial thrombosis, aneurysm, 2.2–50%), neurological (all kinds, especially meningo-encephalitis, 2.3–38.5%), and articular (arthralgia/arthritis/ankylosing spondylitis, 11.6–93%). c) Pathergy test is positive in some patients: 8.6% (in India) to 70.7% (in China). This data was extracted from the five nationwide surveys and the largest case series from BD conference reports and a Pubmed search. Expert commentary: Diagnosis is clinical but classification/diagnosis criteria may help. The best criteria for BD is the International Criteria for Behcet’s Disease (ICBD). BD is a multisystem disease progressing by attacks and remissions. Each attack may resemble the preceding or it may be different in duration, severity, and the systems involved.

4 March 2011 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
FDFereydoun Davatchi
Fereydoun Davatchi
BABahar Sadeghi Abdollahi
Bahar Sadeghi Abdollahi
MMMandana Mohyeddin
Mandana Mohyeddin
FSFarhad Shahram
Farhad Shahram
BNBehrooz Nikbin
Behrooz Nikbin

1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
IKIsabelle Koné-Paut
Isabelle Koné-Paut
FSFahrad Shahram
Fahrad Shahram
MDMartha Darce-Bello
Martha Darce-Bello
LCLuca Cantarini
Luca Cantarini
RCRolando Cimaz
Rolando Cimaz
PGPEDBD group
PEDBD group
Background We aimed to describe the main features of Behçet's disease (BD) in children in the largest prospective cohort to date and to propose a classification. Methods An international expert consensus group was formed to define a data set of minimal symptoms for the inclusion of patients. Patients were entered prospectively during 66 months. Experts classified patients on a consensus basis. The concordance of two international classifications was analysed in confirmed patients with BD. Comparisons of subgroups of patients helped define consensus criteria. BD-associated clinical manifestations were also investigated in three control diseases extracted from an independent data set (Eurofever). Findings In total, 42 centres from 12 countries included 230 patients; data for 219 (M/F ratio=1) could be analysed. The experts classified 156 patients (71.2%) as having confirmed BD. Males more often than females showed cutaneous, ocular and vascular symptoms and females more often genital aphthosis. Age at disease onset and skin and vascular involvement were lower for European than non-European children. Oral aphthosis was the presenting sign for 81% (179/219) of patients. The mean delay to the second symptom was 2.9±2.2 years. International classifications were not concordant with the expert classification. Our paediatric classification contains six categories, a minimum of three signs (each in a distinct category) defining paediatric BD. Three clinical signs discriminated our cohort from the Eurofever cohorts. Interpretation We present a comprehensive description of a large cohort of patients from both European and non-European countries and propose the first classification of paediatric BD for future therapeutic trials.

31 March 2010 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FDFereydoun Davatchi
Fereydoun Davatchi
FSFarhad Shahram
Farhad Shahram
CCCheyda Chams-Davatchi
Cheyda Chams-Davatchi
HSHormoz Shams
Hormoz Shams
ANAbdolhadi Nadji
Abdolhadi Nadji
BABahar Sadeghi Abdollahi
Bahar Sadeghi Abdollahi

3 August 2010 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
FDFereydoun Davatchi
Fereydoun Davatchi
HSHormoz Shams
Hormoz Shams
MRMozhgan Rezaipoor
Mozhgan Rezaipoor
BSBahar Sadeghi‐Abdollahi
Bahar Sadeghi‐Abdollahi
FSFarhad Shahram
Farhad Shahram
NNNasim Naderi
Nasim Naderi